



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated February 06, 2020**

To,  
National Stock Exchange of India Limited,  
BSE Limited  
**Symbol: GRANULES Scrip Code: 532482**

**Sub: Granules Pharmaceuticals, Inc. received US FDA approval for Colchicine Tablets**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc., a wholly owned foreign subsidiary of Granules India Limited for Colchicine Tablets USP, 0.6 mg. It is bioequivalent to the reference listed drug product (RLD), Colcris Tablets, 0.6 mg, of Takeda Pharmaceuticals USA, Inc. This marks the first Paragraph 4 application from Granules.

Colchicine Tablets are used for treatment of Familial Mediterranean Fever (FMF).

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

**FOR GRANULES INDIA LIMITED**

*J. Chaitanya*

**CHAITANYA TUMMALA  
COMPANY SECRETARY  
COMPLIANCE OFFICER**